Nebulized Hypertonic Saline for Bronchiolitis
Recruitment status was Recruiting
In randomized controlled trials, the use of nebulized hypertonic saline in acute bronchiolitis has been reported to improve respiratory distress scores, to reduce length of hospital stay and to show a trend towards lower hospitalization rates.
The investigators aim to verify by an observational study if the rate of hospital admission and the length of hospital stay of infants presenting to the emergency department (ED) with bronchiolitis decreases after the inclusion of 5.85% nebulized hypertonic saline in the treatment strategy of the ED and hospitalization wards.
The investigators will assess the evolution of hospital admission rates and the length of hospital stay in two hospitals that use 5.85% nebulized hypertonic saline for the treatment of bronchiolitis and in two hospital that do not use these nebulizations. If nebulized hypertonic saline is effective in this setting, then the hospitalization rates and length of stay should be lower during the year of hypertonic saline use compared to two previous years when this therapy was not used. These parameters would not be modified in centers that do not use hypertonic saline.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Observational Study on the Use of Hypertonic Saline for the Treatment of Bronchiolitis|
- Hospitalization rate [ Time Frame: 6 MONTHS ] [ Designated as safety issue: No ]Comparison of hospitalization rates of infants presenting to the ED with bronchiolitis during the year of use of nebulized hypertonic saline versus the two previous years when nebulized hypertonic saline was not used.
- Length of hospital stay [ Time Frame: 6 months ] [ Designated as safety issue: No ]Comparison of lenghts of stay of infants hospitalized for bronchiolitis during the year of use of nebulized hypertonic saline in hospitalization wards versus the two previous years when nebulized hypertonic saline was not used.
- Assessment of 5.85% hypertonic saline tolerance [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]A standardized assessment of the respiratory status will be carried out right before and after each nebulization
|Study Start Date:||November 2011|
|Estimated Study Completion Date:||May 2013|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
This is a before-after observational study designed to compare the results in terms of hospitalization rate and length of hospital stay between a period when nebulized hypertonic saline was included in the treatment of bronchiolitis in infants versus the two previous years when this therapy was not used in two hospitals. There will not be any randomization.
Physicians have been instructed on the use of hypertonic saline for moderate and severe bronchiolitis in infants but its totally up to them whether to use this nebulization for each particular patient. Two other hospital where nebulized hypertonic saline has never been used and will not be used during the next bronchiolitis epidemics will be the control centers.
The study comprises two periods, one prospective starting on November 2011 and ending in March 2012 and one retrospective including the two previous bronchiolitis epidemics, November 2009-March 2012 and November 2010-March 2011.
During the prospective period a standardized assessment of the respiratory status of each infant will be carried out before and after each hypertonic saline nebulization.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01460524
|Contact: Ricardo Carbajal, MD, PhD||+33 firstname.lastname@example.org|
|Contact: Emilie Courtois, RN||+33 email@example.com|
|Hôpital Jean Verdier||Recruiting|
|Bondy, Ile-de-France, France, 93143|
|Contact: Loïc de Ponctual, Professor +33 148026454 firstname.lastname@example.org|
|Principal Investigator: Loïc de Ponctual, MD, Professor|
|Hôpital de Versailles||Recruiting|
|Le Chesnay, France, 78157|
|Contact: Pierre Foucaud, MD +33 139638944 email@example.com|
|Principal Investigator: Pierre Foucaud, MD|
|Hôpital Armand Trousseau||Recruiting|
|Paris, France, 75012|
|Contact: Ricardo Carbajal, MD, PhD +33 144736487 firstname.lastname@example.org|
|Principal Investigator: Jean-Baptiste Armengaud, MD|
|Sub-Investigator: Nathalie de Suremain, MD|
|Sub-Investigator: Emilie Courtois, RN|
|Sub-Investigator: Emmanuel Grimprel, MD, PhD|
|Sub-Investigator: Guillaume Thouvenin, MD|
|Hôpital Robert Debré||Recruiting|
|Paris, France, 75019|
|Contact: François Angoulvant, MD +33 140032186 email@example.com|
|Principal Investigator: François Angoulvant, MD|
|CHI Poissy Saint Germain en Laye||Recruiting|
|Poissy, France, 78300|
|Contact: Béatrice Pellegrino, MD +33 139274050 firstname.lastname@example.org|
|Principal Investigator: Béatrice Pellegrino, MD|
|Principal Investigator:||Ricardo Carbajal, MD, PhD||Hôpital Armand Trousseau, Paris|